Psychiatry is increasingly combining new pharmacogenomic findings with therapeutic drug monitoring (TDM) to improve the safety and efficacy of pharmacotherapy. However, a distinction should be made between “nice to know” and “need to know” pharmacogenomic data because many results are statistically significant in meta-analyses but are not clinically relevant due to their low effect sizes. Some examples will illustrate this integration.

Document Type


Publication Date


Notes/Citation Information

Published in Clinical Pharmacology & Therapeutics, v. 95, issue 3, p. 254-257.

This is the peer reviewed version of the following article: Crettol, S., de Leon, J., Hiemke, C. and Eap, C. B. (2014), Pharmacogenomics in Psychiatry: From Therapeutic Drug Monitoring to Genomic Medicine. Clinical Pharmacology & Therapeutics, 95: 254–257., which has been published in final form at http://dx.doi.org/ 10.1038/clpt.2013.221 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Digital Object Identifier (DOI)

http://dx.doi.org/ 10.1038/clpt.2013.221